BC mortality rates vary by subtype, with TNBC at around 30%, luminal B at 20%–25%, HER-2-positive at 20%, and luminal A at 10%–15% (Hennigs et al., 2016; André et al., 2019; Gnant et al., 2022; Wynn and Tang, 2022; Hassan and Ates-Alagoz, 2023). The gene discussed is ERBB2; the disease is breast cancer.